Intelligence

White paper: Improve the drug discovery tool box

Making good decisions in the drug discovery process requires software to effectively manage the size and complexity of multiparametric datasets. Companies that most quickly and accurately identify key drug discovery parameters will win the race to identify the most appropriate targets and develop medicines to affect them.

#Intelligence #Resources

Automation that connects your drug discovery workflow

Scientific and technological advancements continue to emphasise the importance of automation, both in the physical and digital world. Given recent discussions about the lab of the future, the benefits have expanded to highlight how automation can support greater connectivity between data and workflows, paving the way to a ‘smarter lab’. Read More

#Intelligence #Resources

#Biopharmaceuticals #Biotechnology #Drug discovery #Market reporting #Pharmatech

Pharma report predicts growth of contract services by 2025

A post-pandemic pharma report from CPhI predicts the next few years will deliver strong growth in pharma innovation, with oncology and rare diseases potentially the biggest beneficiaries of positive Covid-19 legacies – including accelerated development timelines, remote trials and new technologies in genetic and target screening. The report anticipates breakthroughs in… Read More

#Market Reports #News

Your guide to fragment-based drug discovery

Fragment-based drug discovery (FBDD) is one of the most popular approaches for finding lead compounds and it is becoming more widely adopted by pharma companies. FBDD is the solution researchers turn to when faced with challenging targets that call for compound libraries that offer more diverse molecules — especially from… Read More

#DDW eBooks

Maximize your productivity with high-throughput flow cytometry automation

High-throughput flow cytometry technologies have revolutionized drug screening, says Bio-Rad. This application note explains how you can take throughput and reproducibility to the next level using the ZE5 Cell Analyzer. In the current environment, with increased pressures on drug companies, Bio-Rad believes using effective automation is critical. Featured in this… Read More

#Resources

#CRISPR

Horizon’s iPSC cell line engineering services

Horizon can help researchers work with the biologically relevant cell models (immune cells, induced pluripotent derived cardiac and neural cells, and organoids) that closely mimic the end-stage biology of interest. With over a decade of CRISPR/Cas cell line engineering experience, Horizon’s iPSC editing platform is designed to enable efficient and… Read More

#Resources

#Antibodies

A rapid method to quantitatively screen bispecific antibody using protein A and His1K biosensors

Recent biotechnological advances have fueled development bispecific antibodies (bsAbs) in the last 10 years. However, the functional analysis of bsAbs during bioprocessing adds a challenge for scientists given the wide array of bsAbs populated by many different species, comprising many different formats, and that traditional SPR and ELISA methods for… Read More

#Resources

#Biotechnology

Innovation and opportunity: Biotech at its best

Lu Rahman looks at the role of the biotech sector in the development of new therapeutics and why this industry is a vital element in drug discovery For reasons we would clearly have preferred not to happen, the global spotlight has  – understandably – been on the biotech sector since… Read More

#Market Reports #News

#AI / data analytics / healthtech / informatics #Drug discovery

Precision medicine in the era of artificial intelligence

Dr Lotfi Chouchane and Dr. Javaid Sheikh, Weill Cornell Medicine-Qatar, outline the challenges and opportunities ahead for drug discovery Precision medicine is an emerging model for the next generation of clinical care that will capitalise on the dynamic interaction between individual biology, lifestyle, behaviour, and environment. It holds huge promise… Read More

#Exclusive Content #News #Trends & Analysis

#Metabolomics #Pharmaceuticals #Research & development

Boosting pharmaceutical research with microbiome data

Microbiome-based evidence is set to drive understanding of how drugs interact with human ‘host’ environments, helping devise more targeted treatments and create business opportunities, reports Anthony Finbow, CEO of Eagle Genomics. The microbiology of the drug recipient impacts their immune response, allergic responses and more. Increasingly, life sciences R&D is… Read More

#Editor's Choice #Exclusive Content #News #Trends & Analysis

#Bioinformatics #Informatics #Pharmaceutical #Phosphoproteomic

Is this start-up a game changer for drug discovery?  

Jane Theaker, Kinomica explains why she was so impressed with the preclinical datasets predicting for drug response that the company could produce, she decided to join as CEO. Kinomica is a spin out offering phosphoproteomic analyses to the pharmaceutical industry. Theaker has R&D expertise in novel diagnostic technologies. Her experience… Read More

#News #Start-up Zone

#AI / data analytics / healthtech / informatics #Biomarkers #Drug discovery

2020 overview for AI for drug discovery, biomarker development and advanced R&D

Deep Pharma Intelligence announces the release of a new, open-access 130-page analytical report and interactive analytics Dashboard: AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020. This delivers advanced market intelligence, interactive mindmaps, benchmarking for companies, investors and technologies, competitive and SWOT analysis through the interactive IT-Platform and… Read More

#Editor's Choice #Market Reports #News